Ireland
--:--IST
Recruiting Not applicable

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

NCT03945305 · tracked via the Priya Life Science China tracker
Sponsor
Phase
Not applicable
Started
2023-11-25
Last updated
2026-07-28

Condition(s) studied

Essential Hypertension

Investigational drug(s) / intervention(s)

Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.Previous antihypertensive treatment

Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.

Previous antihypertensive treatment: Patients are only treated with previous antihypertensive treatment.

Study summary

The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.

Eligibility

Sex
ALL
Min age
30 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age≥30 years, ≤ 75 years, regardless of sex; 2. Patients with a history of essential hypertension and systolic blood pressure (SBP) ≥140 mmHg in three blood pressure measurements performed on separate days within 3 days prior to enrollment. 3. Signed and dated informed consent is obtained. Exclusion Criteria: 1. Blood pressure ≥ 180/110mmHg; 2. Planned adjustment of antihypertensive drugs within the next 3 weeks; 3. Severe hematologic disorders or significant coagulation abnormalities; 4. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 5. Pregnant or lactating women; 6. Severe hepatic and renal dysfunction; 7. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; 8. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.

Primary outcome measure(s)

  • Changes of mean systolic blood pressure — 12-14 days
    The mean systolic blood pressure in the last 3 days of treatment minus baseline mean systolic blood pressure

Trial sites (1)

FacilityCityRegionStatus
First Hospital of Jilin University Changchun Jilin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03945305 on ClinicalTrials.gov ↗ ← All trials in China